Sugi Predict

Sugi Predict / Compounds / SCHEMBL745692

SCHEMBL745692

SCHEMBL745692

FC(F)(F)c1cc2cc(Br)ccc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.47
▸ AHR P35869 2/20 0.47
▸ CYP2A6 P11509 1/20 0.47
▸ NR4A2 P43354 1/20 0.47
▸ KDM4E B2RXH2 4/20 0.41
▸ IDO1 P14902 1/20 0.40
▸ NOS1 P29475 1/20 0.40
▸ METAP2 P50579 1/20 0.40
▸ CSNK2A1 P68400 1/20 0.40
▸ FLT3 P36888 1/20 0.39
▸ CRHBP P24387 1/20 0.37
▸ CRHR2 Q13324 1/20 0.37
▸ HRH4 Q9H3N8 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37
▸ CHRNA7 P36544 3/20 0.36
▸ KCNH2 Q12809 3/20 0.36
▸ GPR183 P32249 1/20 0.36
▸ CNR1 P21554 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17351229 0.85 AHR (0.47) AHRCYP2A6NR4A2KDM4ENOS1
SCHEMBL26262642 0.81 CYP19A1 (0.47) CYP19A1AHRCYP2A6NR4A2NOS1
SCHEMBL28132432 0.78 LOXL2 (0.50) CYP19A1AHRNR4A2KDM4ENOS1
SCHEMBL21959783 0.77 KDM4E (0.60) CYP2A6KDM4EFLT3CHRNA7KCNH2
SCHEMBL19753215 0.77 CYP2A6 (0.53) CYP2A6KDM4ECRHBPCRHR2HRH4
SCHEMBL2005505 0.77 FLT3 (0.50) KDM4EFLT3
SCHEMBL2486296 0.75 CYP19A1 (0.53) CYP19A1AHRCYP2A6NR4A2KDM4E
SCHEMBL24801287 0.75 TDP2 (0.49) KDM4EMETAP2FLT3MEN1POLB
SCHEMBL30806289 0.75 HCAR1 (0.44) CYP19A1AHRCYP2A6NR4A2IDO1
SCHEMBL12330508 0.75 FLT3 (0.44) CYP19A1AHRCYP2A6NR4A2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS DONG-A ST CO., LTD. (KR) 2026-05-28 — — US disclosed
US-20260070880-A1 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES, INC. (US) 2026-03-12 — — US disclosed
EP-4605395-A2 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS Dong-A ST Co., Ltd. (KR) 2025-08-27 — — EP disclosed
EP-4583868-A2 DYNAMIN ACTIVATORS Walden Biosciences, Inc. (US) 2025-07-16 — — EP disclosed
WO-2025082069-A1 COMPOUND BINDING TO CRBN PROTEIN AND DEGRADATION AGENT OF PROTEIN 中国海洋大学 2025-04-24 — — WO disclosed
CN-119841843-A Compound combined with CRBN protein and degradation agent of CRBN protein 中国海洋大学 2025-04-18 — — CN disclosed
WO-2024084448-A2 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS DONG-A ST CO., LTD. (KR) 2024-04-25 — — WO disclosed
WO-2024054661-A2 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES (US) 2024-03-14 — — WO disclosed
EP-3517524-B1 PARASITICIDAL COMPOSITIONS COMPRISING INDOLE DERIVATIVES, METHODS AND USES THEREOF BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) 2021-05-26 — — EP disclosed
EP-3517524-B1 PARASITICIDAL COMPOSITIONS COMPRISING INDOLE DERIVATIVES, METHODS AND USES THEREOF BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) 2021-05-26 — — EP disclosed
EP-1896469-A2 FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2008-03-12 — — EP disclosed
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES ABBVIE INC. 2008-02-21 — — US disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 — — US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 — — US disclosed
WO-2007018738-A2 FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2007-02-15 — — WO disclosed
CN-1856498-A Thienopyridine and furopyridine kinase inhibitors ABBOTT LAB (US) 2006-11-01 — — CN disclosed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 — — EP disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 — — US disclosed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 — — WO disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES MALT1, BMP2, ALKBH2 CYP19A1 16/4885AHR 130/4885CYP2A6 75/4885
US-20260070880-A1 DYNAMIN ACTIVATORS DNM1, DNM1L, DNM2 CYP19A1 4221/4885AHR 4553/4885CYP2A6 3646/4885
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK CYP19A1 3799/4885AHR 3249/4885CYP2A6 3411/4885
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS AXL, ERBB2, ERBB3 CYP19A1 3989/4885AHR 198/4885CYP2A6 3283/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK CYP19A1 3799/4885AHR 3249/4885CYP2A6 3411/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK CYP19A1 3799/4885AHR 3249/4885CYP2A6 3411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.